Cargando…
CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers
World Health Organization (WHO) data show that of the top 20 factors that threaten human life and health, cancer is at the forefront, and the therapeutic approaches for cancer consist of surgery, radiotherapy, chemotherapy and immunotherapy. For most highly metastatic and recurrent cancer, radiation...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966018/ https://www.ncbi.nlm.nih.gov/pubmed/35372031 http://dx.doi.org/10.3389/fonc.2022.854678 |
_version_ | 1784678564995530752 |
---|---|
author | Wu, Xixi Wu, Junying Wang, Lingxia Yang, Wei Wang, Bo Yang, Huan |
author_facet | Wu, Xixi Wu, Junying Wang, Lingxia Yang, Wei Wang, Bo Yang, Huan |
author_sort | Wu, Xixi |
collection | PubMed |
description | World Health Organization (WHO) data show that of the top 20 factors that threaten human life and health, cancer is at the forefront, and the therapeutic approaches for cancer consist of surgery, radiotherapy, chemotherapy and immunotherapy. For most highly metastatic and recurrent cancer, radiation therapy is an essential modality to mitigate tumor burden and improve patient survival. Despite the great accomplishments that have been made in clinical therapy, an inevitable challenge in effective treatment is radioresistance, the mechanisms of which have not yet been completely elucidated. In addition, radiosensitization methods based on molecular mechanisms and targets, and clinical applications are still inadequate. Evidence indicates that circular RNAs (circRNAs) are important components in altering tumor progression, and in influencing resistance and susceptibility to radiotherapy. This review summarizes the reasons for tumor radiotherapy resistance induced by circRNAs, and clarifies the molecular mechanisms and targets of action. Moreover, we determine the potential value of circRNAs as clinical indicators in radiotherapy, providing a theoretical basis for circRNAs-based strategies for cancer radiotherapy. |
format | Online Article Text |
id | pubmed-8966018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89660182022-03-31 CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers Wu, Xixi Wu, Junying Wang, Lingxia Yang, Wei Wang, Bo Yang, Huan Front Oncol Oncology World Health Organization (WHO) data show that of the top 20 factors that threaten human life and health, cancer is at the forefront, and the therapeutic approaches for cancer consist of surgery, radiotherapy, chemotherapy and immunotherapy. For most highly metastatic and recurrent cancer, radiation therapy is an essential modality to mitigate tumor burden and improve patient survival. Despite the great accomplishments that have been made in clinical therapy, an inevitable challenge in effective treatment is radioresistance, the mechanisms of which have not yet been completely elucidated. In addition, radiosensitization methods based on molecular mechanisms and targets, and clinical applications are still inadequate. Evidence indicates that circular RNAs (circRNAs) are important components in altering tumor progression, and in influencing resistance and susceptibility to radiotherapy. This review summarizes the reasons for tumor radiotherapy resistance induced by circRNAs, and clarifies the molecular mechanisms and targets of action. Moreover, we determine the potential value of circRNAs as clinical indicators in radiotherapy, providing a theoretical basis for circRNAs-based strategies for cancer radiotherapy. Frontiers Media S.A. 2022-03-16 /pmc/articles/PMC8966018/ /pubmed/35372031 http://dx.doi.org/10.3389/fonc.2022.854678 Text en Copyright © 2022 Wu, Wu, Wang, Yang, Wang and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wu, Xixi Wu, Junying Wang, Lingxia Yang, Wei Wang, Bo Yang, Huan CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers |
title | CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers |
title_full | CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers |
title_fullStr | CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers |
title_full_unstemmed | CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers |
title_short | CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers |
title_sort | circrnas in malignant tumor radiation: the new frontier as radiotherapy biomarkers |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966018/ https://www.ncbi.nlm.nih.gov/pubmed/35372031 http://dx.doi.org/10.3389/fonc.2022.854678 |
work_keys_str_mv | AT wuxixi circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers AT wujunying circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers AT wanglingxia circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers AT yangwei circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers AT wangbo circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers AT yanghuan circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers |